Junshi Biological: JS015 injection liquid clinical trial application for acceptance

On August 17, 2022, Junshi Biological (01877.HK) announced that the company received the "Acceptance Notice" approved by the relevant department, and the clinical trial application of the JS015 injection (project code "JS015") was accepted.

JS015 is the company's independent and independent reorganized humanized anti -DKK1 monoclonal antibody injection, which is mainly used for the treatment of late malignant physical tumors. DKK1 (DICKOPF-) is a secretion-type protein of the DKK family. It is highly expressed on multiple tumor cells such as multiple gastric cancer, gastric spouse junction, osteoma, liver cancer, lung cancer, ovarian cancer, etc. Classic WNT signaling pathway. JS015 can combine people DKK1 with high affinity, and can effectively block the interaction between DKK1 and its ligand LRP5/6 and activate the WNT signaling pathway.

At the same time, JS015 can inhibit the immunosuppressive effect of DKK1 in the micro -environment of the tumor and enhance the ability of the immune system to kill tumor cells. Research on drug effects before clinical showing that JS015 single medicine, joint company commercialized product Tripley Mipide (product name :: Takiyi®, Product code: JS001) or combined with paclitaxel has a significant tumor suppression effect. In addition, animals have good tolerance to JS015. As of the date of the announcement, there are no similar target products at home and abroad.

- END -